Impax Announces the Retirement of Nigel Ten Fleming, Ph.D. and Michael Markbreiter from its Board of Directors

April 14, 2016

HAYWARD, Calif., April 14, 2016 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Nigel Ten Fleming, Ph.D. and Michael Markbreiter, who are distinguished, longtime members of the Company's Board of Directors will retire from the Board at the Company's 2016 annual meeting of stockholders and will not stand for re-election at the meeting.

"On behalf of the Board of Directors, we thank Nigel and Michael for their distinguished service to the Company over many years," said Robert L. Burr, Chairman of Impax. "Nigel and Michael have been members of the Board since 1999 and 1997, respectively, and we are extremely grateful for their leadership, guidance and countless contributions. Their efforts have resulted in a stronger company and more effective and diverse board."

Fred Wilkinson, President and CEO of Impax, said: "On behalf of the executive management team and the entire employee base, I would like to thank Nigel and Michael for their many years of service to Impax and its stockholders. During their tenure, all of us have greatly benefited from their insight, counsel and leadership during a time of significant growth and transformation for our company."

About Impax Laboratories, Inc.
Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments. For more information, please visit the Company's Web site at:

Company Contacts:
Mark Donohue
Investor Relations and Corporate Communications  
(215) 558-4526

To view the original version on PR Newswire, visit:

SOURCE Impax Laboratories, Inc.